← All trials
NCT05045872
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2021
- Primary completion
- Jun 30, 2022
- Completion date
- Sep 30, 2022
- First posted
- Sep 16, 2021
- Last posted
- Sep 16, 2021
- Enrollment
- 40
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Nanjing Medical UniversityLead sponsor
- Jiangsu Chia-tai Tianqing Pharmaceutical Co.,LtdCollaborator
- Nanjing Medical UniversityReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.